Imaging agents for in vivo molecular profiling of disseminated prostate cancer: Cellular processing of [In-111]-labeled CHX-A "DTPA-trastuzumab and anti-HER2 ABY-025 Affibody in prostate cancer cell lines
2011 (English)In: Experimental and Therapeutic Medicine, ISSN 1792-0981, Vol. 2, no 3, 523-528 p.Article in journal (Refereed) Published
The treatment of disseminated prostate cancer remains a great challenge in current oncology practice. The proliferation of prostate cancer cells is testosterone-driven, but clonal selection during androgen deprivation therapy promotes the development of androgen-independent (hormone-refractory) cells, which become phenotypically dominant. Human epidermal growth factor receptor type 2 (HER2) is capable of activating the androgen receptor pathway, even in the absence of the ligand. The detection of phenotypic changes associated with the development of androgen independence may influence patient management, suggesting the initiation of a second-line therapy. This study aimed to establish the level of HER2 expression in a number of prostate cancer cell lines (LNCaP, PC3 and DU145) in order that they be used as models in further studies, and to evaluate the binding and cellular processing of [In-111]-labeled trastuzumab and the anti-HER2 synthetic Affibody molecule ABY-025 in these cell lines. The expression of HER2 was demonstrated and quantified in all three tested prostate cancer cell-lines. Studies on cellular processing demonstrated that internalization of both conjugates increased continuously during the whole incubation. The internalization rate was approximately equal for both monoclonal antibodies and Affibody molecules. In both cases, internalization was moderately rapid. Such features would definitely favor the use of radiometal labels for trastuzumab and, most likely, for affibody molecules. The level of HER2 expression in these cell lines is sufficient for in vivo molecular imaging.
Place, publisher, year, edition, pages
2011. Vol. 2, no 3, 523-528 p.
human epidermal growth factor receptor type 2, prostate cancer, trastuzumab, Affibody molecule, DU145, PC3, LNCaP, indium-111, in vitro, cellular processing
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:uu:diva-153296DOI: 10.3892/etm.2011.217ISI: 000289818200023OAI: oai:DiVA.org:uu-153296DiVA: diva2:416021